Google
AUPH 株価分析 — Aurinia Pharmaceuticals Inc (Healthcare >> Biotechnology)
AUPH に関するよくある質問
AUPHのPER（株価収益率）は？
Aurinia Pharmaceuticals Inc（AUPH）は現在PER 6.47倍で取引されています。
AUPHのROE（自己資本利益率）は？
Aurinia Pharmaceuticals IncのROEは52.54%です。
AUPHの配当利回りは？
Aurinia Pharmaceuticals Incの配当利回りは0.00%です。
AUPHの品質スコア（Quality Score）は？
当社のAIはAUPHの総合財務品質を100点中100点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
AUPHは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
AUPHはどのセクターに属しますか？
Aurinia Pharmaceuticals IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
AUPH AI Analysis Summary
Our AI summary for AUPH: Aurinia Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 6.47, ROE of 52.54%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 14.88
Price
-0.12
(-0.80%)
Day Change
|
|
|---|
AUPH, ファンダメンタルスコアはexcellent ( ファンダメンタル = 100) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Excellent
- Reason
-
Company financial health is Excellent from almost all quality indicators
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
64% |
| In Recommendations? | In "Invest - GROWTH" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 5.66 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
82
GOOD
|
| Magic Formula Rank by ROE |
82
GOOD
|
| Magic Formula Rank by ROIC |
149
|
| Price | 14.88 |
| PBV / Sector |
3.40 / 5.20
|
| Earning Per Share | 2.30 |
| PE / Sector |
6.47 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
17.98 M
GREAT
|
| Average 1W Daily Value |
18.93 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:30 |
| Symbol | AUPH |
| Name | AURINIA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 128.60 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,929.03 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6
Phone: 250 744 2487
Website: https://www.auriniapharma.com
Employees: 128
Sector: Healthcare >> Biotechnology
Description: Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
